Trial Profile
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs MB 107 (Primary) ; Busulfan; Palifermin
- Indications Immunodeficiency disorders; X-linked genetic disorders
- Focus Pharmacogenomic; Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2032.
- 08 Mar 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2032.
- 27 Jan 2024 Planned number of patients changed from 30 to 40.